HER2/neu Overexpression and Recurrence Risk in Early Stage Uterine Serous Carcinoma

被引：0
|
作者：
Blakaj, A. [1 ]
Jairam, V. [2 ]
Buza, N. [3 ]
Schwartz, P. [4 ]
Santin, A. [4 ]
Damast, S. [1 ]
机构：
[1] Yale Sch Med, Dept Therapeut Radiol, New Haven, CT USA
[2] Yale Sch Med, New Haven, CT USA
[3] Yale Sch Med, Dept Pathol, New Haven, CT USA
[4] Yale Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2018年 / 102卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2018.07.139
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1126
引用
收藏
页码：S218 / S219
页数：2
相关论文
共 50 条
  • [1] Evaluation of overexpression of HER2/neu in primary uterine, ovarian, and peritoneal papillary serous carcinoma
    Hatami, M.
    Goldberg, G.
    Whitney, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed?
    Santin, AD
    GYNECOLOGIC ONCOLOGY, 2003, 88 (03) : 263 - 265
  • [3] Her-2/neu overexpression and amplification in uterine papillary serous carcinoma
    Slomovitz, BM
    Broaddus, RR
    Burke, TW
    Sneige, N
    Soliman, PT
    Wu, WG
    Sun, CC
    Munsell, MF
    Gershenson, DM
    Lu, KH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) : 3126 - 3132
  • [4] Clinical significance of Her-2/neu overexpression in uterine serous carcinoma
    Díaz-Montes, TP
    Ji, HX
    Sehdev, AES
    Zahurak, ML
    Kurman, RJ
    Armstrong, DK
    Bristow, RE
    GYNECOLOGIC ONCOLOGY, 2006, 100 (01) : 139 - 144
  • [5] Her-2/neu overexpression and amplification in uterine papillary serous carcinoma (UPSC).
    Slomovitz, BM
    Broaddus, RR
    Burke, TW
    Sneige, N
    Gershenson, DM
    Lu, KH
    JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 2004, 11 (02) : 410A - 410A
  • [6] Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma
    Rossi, Emma C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 (01) : 1 - 2
  • [7] Overexpression of HER-2/neu in uterine serous papillary cancer
    Santin, AD
    Bellone, S
    Gokden, M
    Palmieri, M
    Dunn, D
    Agha, J
    Roman, JJ
    Hutchins, L
    Pecorelli, S
    O'Brien, T
    Cannon, MJ
    Parham, GP
    CLINICAL CANCER RESEARCH, 2002, 8 (05) : 1271 - 1279
  • [8] Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
    P Todeschini
    E Cocco
    S Bellone
    J Varughese
    K Lin
    L Carrara
    F Guzzo
    N Buza
    P Hui
    D-A Silasi
    E Ratner
    M Azodi
    P E Schwartz
    T J Rutherford
    S Pecorelli
    A D Santin
    British Journal of Cancer, 2011, 105 : 1176 - 1182
  • [9] Prognostic implications of HER2/neu on chemosensitivity and survival in uterine serous and clear cell carcinoma
    McEachron, Jennifer
    Zhou, Nancy
    Baqir, Agha Wajdan
    Jabbar, Absia
    Gassmann, Kyra
    Gupta, Raavi
    Lee, Yi-Chun
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S246 - S247
  • [10] Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
    Todeschini, P.
    Cocco, E.
    Bellone, S.
    Varughese, J.
    Lin, K.
    Carrara, L.
    Guzzo, F.
    Buza, N.
    Hui, P.
    Silasi, D-A
    Ratner, E.
    Azodi, M.
    Schwartz, P. E.
    Rutherford, T. J.
    Pecorelli, S.
    Santin, A. D.
    BRITISH JOURNAL OF CANCER, 2011, 105 (08) : 1176 - 1182
12345